全文获取类型
收费全文 | 159500篇 |
免费 | 10793篇 |
国内免费 | 1224篇 |
专业分类
耳鼻咽喉 | 2238篇 |
儿科学 | 3057篇 |
妇产科学 | 3758篇 |
基础医学 | 23648篇 |
口腔科学 | 3339篇 |
临床医学 | 15084篇 |
内科学 | 30284篇 |
皮肤病学 | 4525篇 |
神经病学 | 11932篇 |
特种医学 | 8090篇 |
外科学 | 21873篇 |
综合类 | 2128篇 |
现状与发展 | 5篇 |
一般理论 | 81篇 |
预防医学 | 9530篇 |
眼科学 | 4260篇 |
药学 | 13583篇 |
中国医学 | 1592篇 |
肿瘤学 | 12510篇 |
出版年
2023年 | 759篇 |
2022年 | 618篇 |
2021年 | 4646篇 |
2020年 | 2468篇 |
2019年 | 3581篇 |
2018年 | 4408篇 |
2017年 | 3242篇 |
2016年 | 4215篇 |
2015年 | 5669篇 |
2014年 | 6940篇 |
2013年 | 8429篇 |
2012年 | 12654篇 |
2011年 | 12292篇 |
2010年 | 7279篇 |
2009年 | 6115篇 |
2008年 | 9268篇 |
2007年 | 9135篇 |
2006年 | 8402篇 |
2005年 | 7989篇 |
2004年 | 7130篇 |
2003年 | 6195篇 |
2002年 | 5386篇 |
2001年 | 4387篇 |
2000年 | 4048篇 |
1999年 | 3302篇 |
1998年 | 1376篇 |
1997年 | 1043篇 |
1996年 | 914篇 |
1995年 | 904篇 |
1994年 | 796篇 |
1993年 | 669篇 |
1992年 | 1623篇 |
1991年 | 1584篇 |
1990年 | 1391篇 |
1989年 | 1275篇 |
1988年 | 1204篇 |
1987年 | 1065篇 |
1986年 | 1034篇 |
1985年 | 893篇 |
1984年 | 677篇 |
1983年 | 577篇 |
1982年 | 412篇 |
1981年 | 396篇 |
1980年 | 353篇 |
1979年 | 516篇 |
1978年 | 413篇 |
1977年 | 392篇 |
1976年 | 353篇 |
1974年 | 358篇 |
1973年 | 334篇 |
排序方式: 共有10000条查询结果,搜索用时 891 毫秒
81.
82.
83.
Su Jeong Seong Jin Pyo Hong Bong-Jin Hahm Hong Jin Jeon Jee Hoon Sohn Jun Young Lee Maeng Je Cho 《Journal of Korean medical science》2015,30(11):1675-1681
While decreasing trend in gender differences in alcohol use disorders was reported in Western countries, the change in Asian countries is unknown. This study aims to explore the shifts in gender difference in alcohol abuse (AA) and dependence (AD) in Korea. We compared the data from two nation-wide community surveys to evaluate gender differences in lifetime AA and AD by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Face-to-face interviews using the Composite International Diagnostic Interview (CIDI) were applied to all subjects in 2001 (n=6,220) and 2011 (n=6,022). Male-to-female ratio of odds was decreased from 6.41 (95% CI, 4.81-8.54) to 4.37 (95% CI, 3.35-5.71) for AA and from 3.75 (95% CI, 2.96-4.75) to 2.40 (95% CI, 1.80-3.19) for AD. Among those aged 18-29, gender gap even became statistically insignificant for AA (OR, 1.59; 95% CI, 0.97-2.63) and AD (OR, 1.18; 95% CI, 0.80-2.41) in 2011. Men generally showed decreased odds for AD (0.55; 95% CI, 0.45-0.67) and women aged 30-39 showed increased odds for AA (2.13; 95% CI 1.18-3.84) in 2011 compared to 2001. Decreased AD in men and increased AA in women seem to contribute to the decrease of gender gap. Increased risk for AA in young women suggests needs for interventions. 相似文献
84.
85.
Hanna Lee Mary K. Tan Andrew T. Yan Paul Angaran Paul Dorian Claudia Bucci Jean C. Gregoire Alan D. Bell Martin S. Green Peter L. Gross Allan Skanes Charles R. Kerr L. Brent Mitchell Jafna L. Cox Vidal Essebag Brett Heilbron Krishnan Ramanathan Carl Fournier Shaun G. Goodman 《The Canadian journal of cardiology》2019,35(2):160-168
Background
Physicians treating nonvalvular atrial fibrillation (AF) assess stroke and bleeding risks when deciding on anticoagulation. The agreement between empirical and physician-estimated risks is unclear. Furthermore, the association between patient and physician sex and anticoagulation decision-making is uncertain.Methods
We pooled data from 2 national primary care physician chart audit databases of patients with AF (Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation and Coordinated National Network to Engage Physicians in the Care and Treatment of Patients with Atrial Fibrillation Chart Audit) with a combined 1035 physicians (133 female, 902 male) and 10,927 patients (4567 female and 6360 male).Results
Male physicians underestimated stroke risk in female patients and overestimated risk in male patients. Female physicians estimated stroke risk well in female patients but underestimated the risk in male patients. Risk of bleeding was underestimated in all. Despite differences in risk assessment by physician and patient sex, > 90% of patients received anticoagulation across all subgroups. There was modest agreement between physician estimated and calculated (ie, CHADS2 score) stroke risk: Kappa scores were 0.41 (0.35-0.47) for female physicians and 0.34 (0.32-0.36) for male physicians.Conclusions
Our study is the first to examine the association between patient and physician sex influences and stroke and bleeding risk estimation in AF. Although there were differences in agreement between physician estimated stroke risk and calculated CHADS2 scores, these differences were small and unlikely to affect clinical practice; further, despite any perceived differences in the accuracy of risk assessment by sex, most patients received anticoagulation. 相似文献86.
87.
88.
Prahlad V. Raninga Andy C. Lee Debottam Sinha Yu-Yin Shih Deepak Mittal Ashwini Makhale Amanda L. Bain Devathri Nanayakarra Kathryn F. Tonissen Murugan Kalimutho Kum Kum Khanna 《International journal of cancer. Journal international du cancer》2020,146(1):123-136
Triple-negative breast cancer (TNBCs) is a very aggressive and lethal form of breast cancer with no effective targeted therapy. Neoadjuvant chemotherapies and radiotherapy remains a mainstay of treatment with only 25–30% of TNBC patients responding. Thus, there is an unmet clinical need to develop novel therapeutic strategies for TNBCs. TNBC cells have increased intracellular oxidative stress and suppressed glutathione, a major antioxidant system, but still, are protected against higher oxidative stress. We screened a panel of antioxidant genes using the TCGA and METABRIC databases and found that expression of the thioredoxin pathway genes is significantly upregulated in TNBC patients compared to non-TNBC patients and is correlated with adverse survival outcomes. Treatment with auranofin (AF), an FDA-approved thioredoxin reductase inhibitor caused specific cell death and impaired the growth of TNBC cells grown as spheroids. Furthermore, AF treatment exerted a significant in vivo antitumor activity in multiple TNBC models including the syngeneic 4T1.2 model, MDA-MB-231 xenograft and patient-derived tumor xenograft by inhibiting thioredoxin redox activity. We, for the first time, showed that AF increased CD8+Ve T-cell tumor infiltration in vivo and upregulated immune checkpoint PD-L1 expression in an ERK1/2-MYC-dependent manner. Moreover, combination of AF with anti-PD-L1 antibody synergistically impaired the growth of 4T1.2 primary tumors. Our data provide a novel therapeutic strategy using AF in combination with anti-PD-L1 antibody that warrants further clinical investigation for TNBC patients. 相似文献
89.
Narges K Tafreshi David L Morse Marie Catherine Lee 《World journal of clinical oncology》2020,11(4):169-179
Triple-negative breast cancer (TNBC) is defined as a type of breast cancer with lack of expression of estrogen receptor, progesterone receptor and human epidermal growth factor 2 protein. In comparison to other types of breast cancer, TNBC characterizes for its aggressive behavior, more prone to early recurrence and a disease with poor response to molecular target therapy. Although TNBC is identified in only 25%-30% of American breast cancer cases annually, these tumors continue to be a therapeutic challenge for clinicians for several reasons: Tumor heterogeneity, limited and toxic systemic therapy options, and often resistance to current standard therapy, characterized by progressive disease on treatment, residual tumor after cytotoxic chemotherapy, and early recurrence after complete surgical excision. Cell-surface targeted therapies have been successful for breast cancer in general, however there are currently no approved cell-surface targeted therapies specifically indicated for TNBC. Recently, several cell-surface targets have been identified as candidates for treatment of TNBC and associated targeted therapies are in development. The purpose of this work is to review the current clinical challenges posed by TNBC, the therapeutic approaches currently in use, and provide an overview of developing cell surface targeting approaches to improve outcomes for treatment resistant TNBC. 相似文献